Sichuan Kelun-Biotech’s Promising Drug Gains Key Approval

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its new drug application for sacituzumab tirumotecan, a treatment for advanced non-small cell lung cancer, has been accepted by China’s National Medical Products Administration. This drug, showing promising results in clinical trials, targets solid tumors and has been prioritized for review. The company has licensed rights to commercialize the drug outside Greater China to Merck & Co., Inc.

For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.